SHH · 688319.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Chengdu Olymvax Biopharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Chengdu Olymvax Biopharmaceuticals Inc.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Chengdu Olymvax Biopharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research, development, and distribution of vaccines. Their current product portfolio includes immunizations against tetanus, a severe and often fatal infectious disease that damages the nervous system due to toxins produced by Clostridium tetani, alongside a vaccine for Haemophilus influenzae type b. Beyond their existing offerings, the company is actively advancing new vaccine candidates targeting Staphylococcus aureus, a prevalent bacterium responsible for both hospital-acquired and community infections, and illnesses associated with Group A streptococcus. This enterprise was established in 2009 and operates from its base in Chengdu, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| CN¥0.08 |
| CN¥160.37M |
| Q2 2024 | Aug 21, 2024 | -CN¥0.00 | CN¥155.00M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥13.49+CN¥0.61 (+4.74%)
Chongqing Zhifei Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
CN¥23.05-CN¥0.12 (-0.52%)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 60.71% below the high.
CN¥10.89-CN¥0.62 (-5.39%)
Walvax Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.83% below the high.
CN¥12.07-CN¥0.14 (-1.15%)
Shenzhen Kangtai Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.04% below the high.
CN¥72.75-CN¥1.05 (-1.42%)
CanSino Biologics Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.64% below the high.
CN¥13.95-CN¥0.17 (-1.2%)
Hualan Biological Bacterin Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.96% below the high.
CN¥15.43-CN¥0.36 (-2.28%)
Changchun BCHT Biotechnology Co.’s quoted price sits in the lower half of its reported 52-week range, 36.94% below the high.
CN¥47.84+CN¥0.18 (+0.38%)
Chengdu Kanghua Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.69% below the high.
